Eli Lilly & Co.

LLY ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-204.1M $2.74B $2.41B $2.39B $4.68B $4.09B $4.35B $5.07B
Depreciation & Amortization $1.57B $1.50B $1.43B $1.38B $1.45B $1.46B $1.37B $1.33B
Depreciation $681.7M $716.2M $717.6M $759.1M $774.8M $754.0M $732.4M $749.1M
Amortization $462.2M $687.9M $631.8M $535.9M $555.0M $563.0M $469.0M $385.7M
Stock-Based Compensation $281.3M $255.3M $217.8M $156.0M $144.9M $141.5M $147.4M $231.0M
Net Cash from Operating Activities $5.62B $4.85B $2.96B $4.46B $5.74B $5.30B $7.23B $6.86B
Investing Activities
Capital Expenditures $1.08B $1.04B $1.07B $1.16B $1.01B $905.4M $672.0M $694.3M
Business Acquisitions $882.1M $45.0M $5.28B $551.4M $43.7M $199.3M $307.8M $609.4M
Net Cash from Investing Activities $-3.78B $-3.14B $26.8M $-3.91B $-2.07B $-2.83B $-4.82B $-3.16B
Financing Activities
Dividends Paid $2.19B $2.16B $2.13B $2.10B $2.12B $2.19B $2.18B $2.17B
Stock Repurchases $299.8M $600.1M $749.5M $800.0M $1.70B $721.1M $0 $0
Net Cash from Financing Activities $142.6M $-559.8M $-3.11B $-166.4M $-3.83B $-4.42B $-2.37B $-2.02B
Net Change in Cash $1.95B $915.7M $-205.2M $41.4M $-188.6M $-1.90B $-70.7M $1.53B
Free Cash Flow $4.54B $3.81B $1.90B $3.30B $4.72B $4.40B $6.56B $6.16B
← Newer Page 2 of 3 Older →